Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 255-255-2 | CAS number: 41198-08-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: inhalation
Administrative data
- Endpoint:
- short-term repeated dose toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Not stated
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Non GLP, no guideline compliant, but broadly similar to the requirements of OECD 412.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 977
- Report date:
- 1977
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 412 (Subacute Inhalation Toxicity: 28-Day Study)
- Deviations:
- not applicable
- GLP compliance:
- no
- Limit test:
- no
Test material
- Reference substance name:
- O-(4-bromo-2-chlorophenyl) O-ethyl S-propyl phosphorothioate
- EC Number:
- 255-255-2
- EC Name:
- O-(4-bromo-2-chlorophenyl) O-ethyl S-propyl phosphorothioate
- Cas Number:
- 41198-08-7
- Molecular formula:
- C11H15BrClO3PS
- IUPAC Name:
- 4-bromo-2-chlorophenyl ethyl (propylsulfanyl)phosphonate
- Test material form:
- liquid
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: RAI
- Sex:
- male/female
Administration / exposure
- Route of administration:
- inhalation: aerosol
- Type of inhalation exposure:
- nose only
- Vehicle:
- air
- Analytical verification of doses or concentrations:
- yes
- Duration of treatment / exposure:
- 6 hrs/day
- Frequency of treatment:
- once daily, 5 days/week for a total of 21 days
Doses / concentrations
- Remarks:
- Doses / Concentrations:0, 68, 219, 449 mg/m3Basis:analytical conc.
- No. of animals per sex per dose:
- 9 animals/sex/gp
- Control animals:
- yes, concurrent vehicle
Results and discussion
Effect levels
- Dose descriptor:
- LOAEC
- Effect level:
- ca. 68 mg/m³ air (analytical)
- Sex:
- male/female
- Basis for effect level:
- other: Based on the reduced feed intake, reduced body weight gains and a signficant reduction in brain cholinesterase activity in erythrocyte in all treated groups
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Mortality:
All animals from the high dose group died within 5 days of the start of dosing. One female from the intermediate dose group died on the fifth experimental day and one control female died on day 16 due to blood collection.
Clinical observations:
Clinical observations were limited to the high dose group, with signs including exophthalmos, dyspnoea, tremor, unkempt fur, partially lateral position and irritation and secretion of the mucous membranes of the eyes and nose. These signs appeared 2 days post initiation of dosing.
Bodyweight:
Bodyweight gain of the males of dosed at 68 and 219 mg/m3 was reduced during the entire exposure period when compared with the control group, whereas that of the females was reduced during the first 10 days only. After that time, the bodyweight of the females was comparable to that of the controls. Animals dosed at 449 mg/m3 all lost weight until they died.
At the end of the recovery period, bodyweight gain was comparable to that of the vehicle control.
Food consumption:
Food consumption of the male rats dosed at 219 mg/m3 was decreased during the entire exposure period, where as that of the females of this group as well as all rats dosed at 68 mg/m3 was decreased during the first week of exposure only.
At the end of the recovery period, food consumption was comparable to that of the vehicle control.
Aerodynamic particle size distribution:
Data was only presented graphically as a distribution for each dose level.
Blood and urinalysis:
Haematological findings:
Haematological parameters tested were comparable for treated and respective control groups for both sexes.
Clinical chemistry findings:
Dose related inhibition of serum, RBC and brain cholinesterase activities were evident in treated rabbits of both sexes. Due to the biological relevance of both RBC and brain cholinesterase activities, only these have been discussed.
High dose: as all animals did prior to the scheduled necropsy, no data was available.
Mid dose: significant inhibition (p<0.01) of both erythrocyte and brain cholinesterase was observed in males (72% and 80% respectively) and females (64% and 80% respectively). The effects on erythrocyte cholinesterase was reversible, however brain cholinesterase activity remained 18 – 30% lower compared to the vehicle controls.
Low dose: significant inhibition (p<0.01) of both erythrocyte and brain cholinesterase was observed in males (64% and 65% respectively) and females (53% and 61% respectively).
Table 7.5.3-1:AChE %inhibition
Dose |
|
Plasma |
RBC |
Brain |
|||||||||
(mg/m3) |
|
Male |
Sig |
Female |
Sig |
Male |
Sig |
Female |
Sig |
Male |
Sig |
Female |
Sig |
0 |
Day 21 |
0 |
|
0 |
|
0 |
|
0 |
|
0 |
|
0 |
|
0 |
Day 42 |
0 |
|
0 |
|
0 |
|
0 |
|
0 |
|
0 |
|
68 |
Day 21 |
35 |
* |
46 |
* |
64 |
* |
53 |
* |
61 |
* |
61 |
* |
219 |
Day 21 |
43 |
* |
59 |
* |
72 |
* |
64 |
* |
80 |
* |
80 |
* |
219 |
Day 42 |
24 |
* |
24 |
* |
-17 |
* |
7 |
* |
18 |
* |
30 |
* |
* p<0.01
Sacrifice and pathology:
Organ weight:
Due to bodyweight loss in both the low and mid dose groups organ/body weight ratios were increased, however organ to brain weights were comparable to the controls.
Gross and histopathology:
Gross pathology: Animals in the high dose group showed acute congestion of all organs. All animals in the mid dose group were slightly emaciated. Animals from the low dose group showed no macroscopic changes which could be attributed to the administration of the test material.
Histopathology: Animals from the high dose group which died in the first week, acute congestion of the parenchymatous organs and also marked congestion of the nasal mucous membranes and in the majority of animals severe interstitial or purulent keratitis were observed. Rats in the low dose group showed only incidental findings which were not attributed to administration of the test material.
Ophthalmic examinations:
Only animals in the high dose group showed signs of irritation of the conjunctivae, all other animals were normal.
Applicant's summary and conclusion
- Conclusions:
- Based on the reduced feed intake, reduced body weight gains and a signficant reduction of cholinesterase activity in erythrocyte and brain in all treated groups a NOAEC could not be established for this study.
- Executive summary:
CGA15324 was administered to rats for 6hours/day, 5 days/week in a 21 -day toxicity (nose only) inhalation study at concentrations of 0, 68, 219 and 449 mg/m3. Nine animals/sex/group; were used, with 4 animals/sex/group kept for a 21 day recovery period following exposure.
All rats from the high dose group and 1 female from the intermediate group died during the 1st week of exposure. Food intake of the males from the intermediate dose group was decreased during the entire exposure period, whereas that of the females of this group as well as all of the rats from the low dose group was decreased during the first week of exposure only.
Bodyweight gain of the male rats of the low and intermediate dose groups was reduced during the entire exposure period when compared with the control group, where as that of the females was reduced during the first 10 days only. At the end of the recovery period the food intake and body weight gain to the males from the intermediate dose group was comparable with that of the controls.
Results of the haematological and blood chemistry analysis were generally unremarkable for both treated rats and controls. Cholinesterase activity of plasma, erythrocyte and brain was significantly depressed in all the groups treated with CGA15324 in a dose-dependent manner. In all cases the approximate level of inhibition was assessed to 40% to 70% of the control values.
Based on the reduced feed intake, reduced body weight gains and a significant reduction of cholinesterase activity in erythrocyte and brain in all treated groups a NOAEC could not be established for this study.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.